MT-601, Marker's lead MAR-T cell therapy, is being evaluated in the nationwide multicenter Phase 1 APOLLO study ( clinicaltrials.gov identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed ...

Myanmar and Thailand search for missing after massive earthquake; Trump talks about running for third term; Trump says new ...

Wow! We received 822 tasty entries in this week’s Cartoon Caption Contest. We had several zany ideas, from Miracle-Gro to ...